on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Position in Avadel Pharmaceuticals
The Vanguard Group, Inc. has released a Form 8.3 concerning its position in Avadel Pharmaceuticals plc. This disclosure, submitted to the Irish Takeover Panel, pertains to relevant securities representing a significant interest, exceeding 1% of Avadel's shares.
As of November 24, 2025, Vanguard reported a holding of 5,572,254 ordinary shares in Avadel, accounting for 5.72% of the company's share capital. Additionally, they executed a purchase of 6,315 shares at $22.92 per unit. These transactions highlight Vanguard's strategic move in the pharmaceutical sector.
No cash-settled or stock-settled derivative positions were reported. Moreover, there are no current agreements, arrangements, or understandings influencing these securities or their voting rights. Vanguard has not attached any Supplemental Form 8 with this disclosure.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news